white → brown1 → yellow2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
TMA-2
2,4,5-Trimethoxyamphetamine
DOMeO, 2,5-Dimethoxy-4-methoxyamphetamine
TMA-2 is a synthetic psychedelic of the substituted amphetamine class and a member of the trimethoxyamphetamine family. First synthesized by Viktor Bruckner in 1933, its psychoactive properties were identified by Alexander Shulgin in 1962.citation needed Structurally related to mescaline but considerably more potent,1 it produces a distinctive combination of hallucinogenic, stimulant, and entactogenic effects. TMA-2 remains an obscure research chemical that is rarely encountered outside of online vendor markets.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~5 mg
Light5-20 mg
Moderate20-40 mg
Strong40-60 mg
Heavy60+ mg
TMA-2 exhibits considerable unpredictability in its effects and demonstrates pronounced dose sensitivity. The margin between doses that produce psychoactive effects and those that may cause toxicity is reported to be narrow. User accounts describe variable responses that commonly include significant body load, nausea, and overstimulation.
Duration
Onset20-120 minutes
Peak4-6 hours
Offset2-4 hours
After Effects4-24 hours
Total8-12 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
TMA-2 produces a mescaline-like psychedelic state layered over mild stimulation, with a notably slow onset — effects may take an hour or more to appear before building to full intensity over the following hour. The character of the experience is frequently described as calm, benign, and peaceful, with an absence of dark or threatening undercurrents, and a somewhat hypnotic quality that can leave users unusually receptive to suggestion. The total duration runs roughly ten to twelve hours, with a fairly rapid drop-off in the later hours at some doses.
Physical
Mental and physical stimulation accompany the experience, alongside come-up discomforts such as nausea, light tremors, and brief intestinal cramping. Pupil dilation, appetite suppression, muscle tension, sweating and chills, and difficulty sleeping toward the end of the experience are also reported.
Autonomic
Uncomfortable
Cognitive
The headspace is calm and lucid, with clear thinking, euphoria, enhanced empathy, insight, and a gently cosmic or ego-softening quality. Time can seem to pass very slowly in the first hours, and mild, non-troublesome confusion is sometimes reported.
Emotional
Enhancements
Visual
Visuals are moderate and well-mannered rather than overwhelming, closely resembling mescaline apart from less intense color enhancement.
Auditory
Tactile
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
TMA-2 acts as a partial agonist at serotonin 5-HT2A receptors, which is believed to be the primary mechanism underlying its psychedelic effects.citation needed It also shows broader activity at the 5-HT2 receptor family.2
Pharmacokinetics
In rat studies, the 4-methoxyl group undergoes preferential O-demethylation, with approximately 20% of that methoxyl carbon appearing as expired carbon dioxide. This rate is roughly four times that observed for either of the other two methoxyl groups, indicating the 4-position is the primary site of oxidative demethylation.citation needed
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects of TMA-2 develops almost immediately after ingestion.
Baseline Reset
Approximately 7 days in the absence of further consumption
Half Tolerance
Approximately 3 days
Cross Tolerance
Psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowTMA-2 is considered to have extremely low addiction potential due to its psychedelic nature. It is not habit-forming and the desire to use it can actually decrease with repeated use, making it largely self-regulating.
Toxicity
Cardiovascular
High doses in rats caused bradycardia and hypothermia;citation needed in humans, vasoconstriction and increased blood pressure have been reported at higher doses, though human data remains extremely limited.
Psychosis Risk
Mental health risks are assumed to be similar to those associated with other hallucinogens. Psychedelic-crisis management is appropriate for acute anxiety and panic reactions. More severe psychotic reactions may occur, especially when someone's family history includes schizophrenia or early-onset mental illness, since psychedelics have been known to trigger latent psychological conditions.
Seizure Risk
Toxicity studies in rats showed that doses of 80 mg/kg induced frequent clonic convulsions.citation needed Given the reported narrow margin between active and toxic doses,1 seizure risk may be elevated at higher dosages. Individuals with seizure or convulsive disorders are advised to exercise particular caution.
History & Culture
TMA-2 was first synthesized by Hungarian chemist Viktor Bruckner in 1933citation needed, but its psychoactive properties remained unrecognized for nearly three decades. Alexander Shulgin independently synthesized the compound in 1962 and conducted the first documented…
Legality
International
The current official Green List is exhaustive for substances under the 1971 Convention. It lists TMA as (±)-3,4,5-trimethoxy-alpha-methylphenethylamine in Schedule I, but does not list TMA-2 / 2,4,5-trimethoxyamphetamine.
By Country
Illegal23
ArgentinaIllegal (analog/blanket ban)Argentina treats substances within the chemical groups in Annex II of Decree 560/2019 as estupefacientes. Annex II's substituted-phenethylamines definition permits an alpha alkyl substituent and one or more ring alkoxy substituents, encompassing TMA-2's alpha-methyl and 2,4,5-trimethoxy substitution pattern; it also expressly covers enantiomers, diastereomers, and their salts.
AustraliaIllegalCriminal Code Regulations 20196
Australia expressly lists TMA-2 by its chemical name, 2,4,5-trimethoxyamphetamine, as a controlled drug under the Criminal Code Regulations 2019. Schedule 1 assigns commercial, marketable, and trafficable quantities of 0.75 kilograms, 250 grams, and 0.75 grams respectively.
AustriaIllegal (SMG)Prohibited under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are illegal.1
CanadaIllegalControlled Drugs and Substances Act, Schedule I, item 19(7)9
TMA-2 is expressly listed as 2,4,5-trimethoxyamphetamine under the amphetamines entry in Schedule I of Canada's Controlled Drugs and Substances Act. Unauthorized possession, trafficking, import/export, and production are prohibited; activities may occur only as authorized by the Act, regulations, or an exemption.
ChileIllegal (analog/blanket ban)Decreto Supremo N.º 867 de 2007, Reglamento de la Ley N.º 20.000, artículo 110
Chile's current consolidated Decreto 867 lists dl-3,4,5-trimetoxi-alfa-metilfeniletilamina (TMA) among the article 1 drugs deemed capable of causing serious toxic effects or considerable harm to health. The same article expressly extends its list to the isomers, esters, and ethers of listed substances unless excepted; TMA-2 (2,4,5-trimethoxyamphetamine) is a positional isomer of the listed 3,4,5-TMA and is therefore covered by that isomer clause rather than named as TMA-2.
DenmarkIllegalTMA-2 is expressly listed as B440 under List B of Denmark's controlled euphoriant substances, under the names 2,4,5-trimethoxyamphetamine and 1-(2,4,5-trimethoxyphenyl)propan-2-amine. List B substances may be used only for medical and scientific purposes.
IrelandIllegal (analog/blanket ban)
JapanIllegalJapan's current designation order lists 2,4,5-trimethoxy-α-methylphenethylamine, the substance commonly known as TMA-2, as a narcotic under Article 1. The listing expressly includes its salts. A Ministry of Health, Labour and Welfare implementation notice identifies the same chemical name with the street name TMA-2 and states that the designation took effect on 13 October 2006.
NetherlandsIllegalOpiumwet (Opium Act), List I24
TMA-2 is expressly listed in List I of the Dutch Opium Act under the name 2,4,5-trimethoxyamfetamine. Article 2 prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing List I substances, subject to statutory exemptions and licences.
PolandIllegalRozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (consolidated text, Dz.U. 2024 poz. 1139)25
Poland lists TMA-2 by name as 2,4,5-trimethoxyamphetamine ("2,4,5-trimetoksyamfetamina") in Annex 1 among Group I-P psychotropic substances. The same Group I-P provision also covers salts where possible and stereoisomers permitted by the listed chemical designation.
SingaporeIllegalTMA-2 is expressly named as 2,4,5-trimethoxy-α-methylphenethylamine in Singapore's controlled-drug legislation, together with its trimethoxy positional isomers in the phenyl ring. The current Misuse of Drugs Regulations place it in the Fourth Schedule of controlled drugs subject to specified licensing, documentation, record-keeping and related requirements; the Misuse of Drugs Act prohibits unauthorised possession, trafficking, manufacture, import, export and consumption of controlled drugs.
SlovakiaIllegalAct No. 139/1998 Coll. on Narcotic Drugs, Psychotropic Substances and Preparations, Annex 131
The official consolidated text effective 1 January 2026 expressly lists TMA-2 (2,4,5-trimethoxyamphetamine) among Group I psychotropic substances in Annex 1. Group I substances are not used as active ingredients in medicines; handling is limited to licensed research, teaching, and expert activities, and handling outside the Act is unlawful. The list also covers salts and stereoisomers of Group I substances where they can exist.
South AfricaIllegal (analog/blanket ban)Drugs and Drug Trafficking Act 140 of 1992, Schedule 2 Part III, as substituted by Drugs and Drug Trafficking Amendment Act 14 of 20223233
TMA-2 is not individually named in Schedule 2 Part III, but 2,5-dimethoxyamphetamine (DMA) is expressly listed. Part III extends every listed substance to all chemically related homologues incorporating a similar structural fragment or exhibiting similar pharmacodynamic properties, which covers TMA-2 as the 4-methoxy homologue of DMA. The Act prohibits use, possession, and dealing in undesirable dependence-producing substances except under its stated lawful exceptions.
SpainIllegalOrden SCO/2359/2004, de 2 de julio34
Use, manufacture, import, transit, trade and possession are prohibited; scientific research requires prior authorization.
TurkeyIllegalClassified as a controlled drug under Turkish law. Possession, production, supply, and import are prohibited.38
United KingdomIllegal (analog/blanket ban)Controlled / restricted2
References
Source Pages
Bluelight: TMA-2 Discussion Thread
Drug Users Bible: TMA-2
Erowid- Erowid: TMA-2 Basics
- Erowid: TMA-2 Experience Reports
- Erowid: TMA-2 Vault
Isomer Design (TiHKAL/PiHKAL)- IsomerDesign PiHKAL: TMA-2
PsychonautWiki
TripSit Factsheets
Wikipedia- Wikipedia: 2,4,5-Trimethoxyamphetamine
- Wikipedia: Trimethoxyamphetamines
Citations
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), & M. Mallaret. (2004). Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs — Chapter 3: Review of the pharmacotoxicological data on TMA-2. Office for Official Publications of the European Communities. https://www.drugsandalcohol.ie/11643/1/EMCDDA_Risk_assessment_TMA2.pdf12345678910
- Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Stratford A, Bhatt S, Halberstadt AL, & Nichols DE. (2019). Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines. https://doi.org/10.3389/fphar.2019.014231
- Shulgin AT, Shulgin A, Shulgin, Alexander T., & Shulgin, Ann. (1991). PiHKAL: A Chemical Love Story — Entry #158 TMA-2. PiHKAL: A Chemical Love Story. https://erowid.org/library/books_online/pihkal/pihkal158.shtml123
- Decreto 560/2019, artículo 2 y Anexo II. argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-560-2019-326675/texto1
- Decreto 560/2019, artículo 2 y Anexo II. servicios.infoleg.gob.ar (n.d.). https://servicios.infoleg.gob.ar/infolegInternet/anexos/325000-329999/326675/dec560-2.pdf1
- Criminal Code Regulations 2019. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2019L00561/2025-03-01/2025-03-01/text/original/pdf1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IVa. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IVa. afmps-fagg.be (n.d.). https://www.afmps-fagg.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf1
- Controlled Drugs and Substances Act, Schedule I, item 19(7). laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
- Decreto Supremo N.º 867 de 2007, Reglamento de la Ley N.º 20.000, artículo 1. nuevo.leychile.cl (n.d.). https://nuevo.leychile.cl/servicios/Consulta/Exportar?exportar_con_notas_al_pie=True&exportar_con_notas_bcn=True&exportar_con_notas_originales=True&exportar_formato=pdf&hddResultadoExportar=269323.2023-09-16.0.0%23&nombrearchivo=DTO-867_19-FEB-2008&radioExportar=Normas1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the TMA-2 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.